ExodusPoint Capital Management’s Filana Therapeutics FLNA Stock Holding History

ExodusPoint Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,275	Closed	-$270K	–	2383
2022 Q1	$270K	Buy	+7,275	New	+$308K	﹤0.01%	1803
2021 Q4	–	Sell	-23,487	Closed	-$1.46M	–	2541
2021 Q3	$1.46M	Buy	+23,487	New	+$1.96M	0.02%	864
2021 Q1	–	Sell	-76,437	Closed	-$521K	–	2538
2020 Q4	$521K	Sell	76,437 -211,933	-73%	-$1.89M	0.01%	1223
2020 Q3	$3.32M	Buy	+288,370	New	+$1.3M	0.07%	257
2020 Q1	–	Sell	-93,780	Closed	-$488K	–	1576
2019 Q4	$488K	Buy	+93,780	New	+$162K	0.01%	870

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

ExodusPoint Capital Management's FLNA Position: Q2 2022 in Review

ExodusPoint Capital Management sold out of Filana Therapeutics (FLNA) in Q2 2022, closing a stake of 7,275 shares — an estimated $270K sold.

ExodusPoint Capital Management first reported a position in FLNA in Q4 2019 and held it in 5 quarters. The position peaked at $3.32M in Q3 2020. 149 funds tracked by Wall St. Rank hold FLNA as of Q2 2022.

ExodusPoint Capital Management reported no remaining Filana Therapeutics position as of Q2 2022 after selling out during the quarter.
ExodusPoint Capital Management sold 7,275 Filana Therapeutics shares in Q2 2022, an estimated $270K.
ExodusPoint Capital Management first reported a position in Filana Therapeutics in Q4 2019 and held it in 5 quarters.
ExodusPoint Capital Management's Filana Therapeutics position peaked at $3.32M in Q3 2020.
149 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.